Exact Sciences Completes 68,000 Cologuard Tests During the Third Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Exact Sciences (EXAS) Beats Q3 EPS by 6c, FY Revenue Guidance Tops Views
October 26, 2016 6:53 AM EDTExact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.36), $0.06 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $28.1 million versus the consensus estimate of $25.1 million.
reported completing 68,000 Cologuard tests vs consensus of 65,400 tests... More